Summary
We have investigated the potential for using cyclosporin A to increase the efficiency with which Epstein-Barr virus-transformed human lymphoblast lines can be prepared. Use of this immunosuppressive drug has permitted the development of a procedure with success rates exceeding 95% despite the processing of very large numbers of samples.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Miller, G.; Lipman, M. Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc. Natl. Acad. Sci. USA 70: 190–194; 1973.
Gusella, J.; Wexler, N.; Conneally, M.; Naylor, S.; Anderson, M.; Tanzi, R.; Watkins, P.; Ottina, K.; Wallace, M.; Sakaguchi, A.; Young, A.; Shoulson, I.; Bonilla, E.; Martin, J. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 306: 234–238; 1983.
Bird, A.; McLachlan, S.; Britton, S. Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein-Barr virus-induced B-cell lines. Nature 289: 300–301; 1981.
Leapman, S.; Filo, R.; Smith, E.; Smith, P. Differential effects of cyclopsorin A on lymphocyte subpopulations. Transplant. Proc. 13: 405–409; 1981.
Moss, D.; Rickinson, A.; Pope, J. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures. Int. J. Cancer 23: 618–625; 1979.
Author information
Authors and Affiliations
Additional information
This work was supported by National Institute of Neurological and Communicative Disorders and Stroke Grants NS16367 (Huntington's Disease Center Without Walls) and NS 20012.
Rights and permissions
About this article
Cite this article
Anderson, M.A., Gusella, J.F. Use of cyclosporin a in establishing epstein-barr virus-transformed human lymphoblastoid cell lines. In Vitro 20, 856–858 (1984). https://doi.org/10.1007/BF02619631
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02619631